TigerOak Management L.L.C. Acquires 156 Shares of Merck & Co., Inc. $MRK

TigerOak Management L.L.C. raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 5.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 2,945 shares of the company’s stock after purchasing an additional 156 shares during the quarter. TigerOak Management L.L.C.’s holdings in Merck & Co., Inc. were worth $233,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barnes Dennig Private Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $27,000. CBIZ Investment Advisory Services LLC raised its position in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after acquiring an additional 221 shares during the last quarter. MorganRosel Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $36,000. Fiduciary Wealth Partners LLC bought a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $48,000. Finally, MJT & Associates Financial Advisory Group Inc. bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at $48,000. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MRK. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company lowered their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Morgan Stanley lowered their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $106.41.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $79.62 on Thursday. The firm has a market cap of $198.88 billion, a PE ratio of 12.27, a PEG ratio of 0.82 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $116.02. The company has a fifty day moving average price of $82.63 and a 200 day moving average price of $82.21.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 4.1%. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.